LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders

Investor-rights firm Halper Sadeh says it is investigating the $102.50/share cash sale of Lantheus Holdings (LNTH) to Curium US Holdings, alongside non-transferable Contingent Value Rights for up to an additional $12.00/share based on product commercial milestones through 2030. The announcement is a cautionary signal for LNTH shareholders ahead of/through the deal process, but the core deal economics remain intact.

Analysis

The market’s real variable here is not operating fundamentals; it is how much of the headline consideration survives legal scrutiny once you haircut the long-dated, non-transferable CVR. In situations like this, the cash leg tends to anchor value, while the CVR is effectively a contingent option that many holders will discount aggressively because it is illiquid, milestone-dependent, and exposed to execution risk through 2030.

The investigation matters mainly because it can slow the timeline and widen the arb spread, not because it is likely to destroy a signed cash deal outright. If anything, it creates a window for improved terms or disclosure around the milestone mechanics, which would be a marginal win for holders and a modest negative for the buyer if the process drags. Second-order, a delayed close can distract management and soften commercial momentum, which is a bigger issue for the company’s competitors in imaging/radiopharma than the market is likely pricing today.

Contrarian view: the consensus may be overestimating the CVR by treating it like near-cash when it is closer to a deep out-of-the-money earnout. The more relevant risk is not litigation noise but a financing, fiduciary, or process issue that pushes the stock away from the implied takeout value for weeks to months. Falsifiers are straightforward: a clean proxy/closing path, no amended terms, and the stock trading tightly to the cash leg; in that case the investigation is just noise and the trade becomes a low-return arb.

Key Decisions for Investors

• Do not initiate a new directional position in LNTH on the investigation alone; wait for the merger spread to dislocate enough to compensate for process risk over the next 1-3 months.
• If LNTH trades at a material discount to the cash consideration, buy the deal spread and hedge market beta with a short XBI basket position; this is a timing trade, not a fundamentals long.
• For existing LNTH holders, mark the CVR near zero or a steep discount in risk models until there is independent evidence that the 2030 milestones are realistically achievable; trim any rally that prices the earnout too generously.
• Set an alert for amended merger terms, financing language, or a competing bid; those are the only catalysts that would justify paying up versus current arb math.